/

AGEN

Agenus Inc.Closed

6.95−0.48 −6.46%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 7.08 +1.87%

Open

7.30

Prev close

7.43

Day range

6.817.34

52-week range

2.7110.31

Volume

991.72K0.64×

Mkt cap

313.88M

P/E ttm

2.75

Fwd P/E

-63.18

EPS ttm

2.53

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−32.59%

Price Chart

Yahoo Finance · delayed

AGENOct 13, 2026O 7.30H 7.34L 6.81C 6.95−0.48 (−6.46%)Vol 991.80K

SMA 507.81
SMA 2004.74

1Y change +75.06% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AGEN Agenus Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.21%
1 month: +0.14%
3 months: +36.81%
6 months: +47.25%
Year to date: +121.34%
1 year: +71.60%

Valuation & ownership

Market cap: 313.88M
Enterprise value: 328.09M
P/E (ttm): 2.75
Forward P/E: -63.18
PEG ratio: 1.44
Price / book: —
Price / sales (ttm): 2.37
EV / EBITDA: 8.08
EPS (ttm): 2.53
EPS (forward): -0.1100
Beta (5y monthly): 1.32
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 45.16M
Float: 40.23M
Short % of float: 15.28%
Short ratio (days): 6.51
Held by insiders: 6.27%
Held by institutions: 46.40%
Avg volume (3m): 1.55M
50-day average: 7.83
200-day average: 4.72
52-week change: +71.60%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 39.8
vs 50-day SMA: −11.01%
vs 200-day SMA: +46.54%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.81%
Realised vol (20d, ann.): 108.1%
From 52-week high: −32.59%
From 52-week low: +156.46%

ANR

Analyst Consensus

3 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

26.33

+278.90% implied

Low 14.00Median 25.00High 40.00

Recommendation trend

Now3 / 0 / 0
1m ago3 / 0 / 0
2m ago

DES

About Agenus Inc.

Yahoo Finance profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 81
Headquarters: Lexington, MA, United States
Website: agenusbio.com
Officers

SEAS

Seasonality · AGEN

2007–2026 · monthly returns

Strongest month Jun +12.30%Weakest month Oct −14.61%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-9.6	17.3	0.3	17.1	-10.5	-12.6	145.1	1.5	30.5	-30.0			+121.3%
2025	38.7	-25.0	-47.0	91.4	18.7	33.2	20.8	-24.3	-7.9	3.1	14.9	-31.1	+14.6%
2024	-19.3	0.0	-13.4	4.5	29.5	6.8	-63.9	-14.7	6.4	-23.4	-18.6	-19.9	−83.5%
2023	8.8	-21.1	-26.2	1.2	3.3	2.6	-5.0	-9.2	-18.1	-29.2	-2.5	6.4	−64.8%
2022	-14.3	-2.2	-8.9	-24.8	-9.7	16.2	33.0	4.7	-24.1	22.4	7.6	-11.1	−25.5%
2021	15.7	8.7	-32.0	13.6	37.9	28.9	-5.6	19.1	-14.9	-26.9	-18.0	2.2	+1.3%
2020	-8.1	-32.4	-3.2	9.0	39.7	5.4	-22.6	43.4	-8.3	-7.8	0.3	-14.1	−21.9%
2019	41.6	-8.3	-3.9	-13.5	-0.8	17.6	-19.7	19.5	-10.4	0.4	61.8	-2.9	+71.0%
2018	10.7	49.3	-12.6	-27.2	-2.3	-32.2	-19.4	20.8	-3.2	-25.7	51.6	-1.2	−27.0%
2017	-2.9	6.0	-11.1	-4.8	-7.5	17.8	13.6	-16.9	19.5	-17.0	7.4	-17.0	−20.9%
2016	-30.6	-12.1	50.2	-15.4	19.9	-4.0	37.0	11.5	16.0	-44.7	3.8	0.0	−9.3%
2015	26.7	-2.6	4.7	28.8	23.8	5.5	-1.0	-16.7	-35.3	-0.9	12.1	-11.2	+14.4%
2014	17.0	58.3	-35.2	-10.4	6.3	6.6	2.5	-4.8	-1.0	-4.2	-0.7	34.1	+50.4%
2013	11.0	-5.9	-9.1	24.9	-17.1	-6.0	1.6	-5.2	-24.1	-12.6	9.1	0.0	−35.6%
2012	39.0	14.7	106.9	-5.3	-16.5	0.4	-7.8	-5.0	0.4	-3.0	-3.1	-5.3	+105.0%
2011	-8.9	-1.1	0.0	4.4	-3.2	-15.2	-1.3	-32.5	-9.6	-2.8	-11.7	-17.4	−67.0%
2010	17.2	2.7	-5.2	58.9	-11.2	-21.4	4.9	-9.4	28.6	-9.1	-1.1	13.5	+57.8%
2009	-20.8	5.3	22.5	44.9	2.8	186.3	4.8	-5.5	0.0	-51.7	-29.0	-9.9	+33.3%
2008	6.4	3.7	4.9	-4.2	2.2	-16.5	2.1	-11.7	-9.2	-52.5	-32.0	-5.9	−76.5%
2007	6.0	-5.7	21.9	42.2	-11.4	1.8	4.2	-16.8	-4.4	8.0	-16.4	-4.7	+11.5%

INSD

Insider Activity · AGEN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 9, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.35 per share.	4.9K	$16.25K
Jun 30, 2026	Harrison Thomas LDirector	Stock Award(Grant) at price 3.58 per share.	8.5K	$30.62K
Jun 25, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.03 per share.	5.4K	$16.25K
Jun 11, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.30 per share.	4.9K	$16.25K
May 28, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.50 per share.	4.6K	$16.25K
May 14, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.58 per share.	4.5K	$16.25K
Apr 30, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.84 per share.	4.2K	$16.25K
Apr 16, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 4.79 per share.	3.4K	$16.30K
Apr 1, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.33 per share.	4.6K	$15.41K
Mar 31, 2026	Harrison Thomas LDirector	Stock Award(Grant) at price 3.32 per share.	9.2K	$30.63K
Mar 19, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.71 per share.	4K	$14.78K
Mar 5, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 2.96 per share.	5K	$14.78K
Feb 19, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.06 per share.	4.8K	$14.78K
Feb 5, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 2.94 per share.	5K	$14.78K
Jan 22, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.24 per share.	4.6K	$14.78K
Jan 8, 2026	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.91 per share.	3.8K	$14.78K
Jan 1, 2026	Harrison Thomas LDirector	Stock Award(Grant) at price 3.23 per share.	7.7K	$24.84K
Dec 25, 2025	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.31 per share.	4.9K	$16.36K
Dec 11, 2025	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 3.79 per share.	4.3K	$16.36K
Nov 27, 2025	Armen Garo H.Chief Executive Officer	Stock Award(Grant) at price 4.56 per share.	3.6K	$16.36K

13F

Investors Holding AGEN

latest 13F filings of 29 followed managers

Investors holding AGEN
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$698.7K	0.00%	228.35K	−20%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

AGEN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AGEN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Agenus Inc.

Seasonality · AGEN

Insider Activity · AGEN

Congress Trades · AGEN

Investors Holding AGEN

Investors Holding AGEN

Congress Trades · AGEN

Insider Activity · AGEN

Seasonality · AGEN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Agenus Inc.

Financial Snapshot

Earnings & Dividends

News